Medifast (MED) Earnings Analysis
Medifast (MED) next reports earnings on 2026-08-03, consensus EPS -0.68 USD. Last quarter (2026-05-04) it beat with EPS -0.19 USD vs -0.55 USD est (+65.5%). It has beaten estimates in 6/8 recent quarters (75%). Trailing P/E -5.36.
Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades
When does MED next report earnings?
| Next earnings date | 2026-08-03 |
|---|---|
| Consensus EPS estimate | -0.68 USD |
| Revenue estimate | 0.07B |
MED earnings history — beats and misses
| Quarter (report date) | EPS actual | EPS est. | Surprise | Result |
|---|---|---|---|---|
| 2026-05-04 | -0.19 USD | -0.55 USD | +65.5% | Beat |
| 2026-02-17 | -0.55 USD | -0.76 USD | +27.6% | Beat |
| 2025-11-03 | -0.21 USD | -0.01 USD | -2000% | Miss |
| 2025-08-04 | 0.04 USD | -0.3 USD | +113.3% | Beat |
| 2025-04-28 | -0.11 USD | -0.07 USD | -57.1% | Miss |
| 2025-02-18 | 0.1 USD | -0.16 USD | +162.5% | Beat |
| 2024-11-04 | 0.35 USD | -0.15 USD | +333.3% | Beat |
| 2024-08-05 | 0.92 USD | 0.36 USD | +155.6% | Beat |
Beat rate: 6/8 (75%) over reported quarters with consensus data.
MED valuation and analyst view
| Trailing P/E | -5.36 |
|---|---|
| Trailing EPS | -1.81919 USD |
| Price / book | 0.54 |
| Dividend yield | 0.00% |
| Market cap | 0.11B |
| Analyst consensus | Hold (4 buy / 6 hold / 2 sell) |
| Avg price target | 12 USD |
Related research pages
Frequently asked questions
When is Medifast (MED)'s next earnings date?
Medifast is next scheduled to report on 2026-08-03, with a consensus EPS estimate of -0.68 USD and revenue estimate of 0.07B.
Did MED beat earnings last quarter?
In its 2026-05-04 report, MED posted EPS of -0.19 USD versus a -0.55 USD estimate — a beat of 65.5%.
What is MED's earnings track record?
Over the last 8 reported quarters with consensus data, MED beat estimates 6 times (75%).
What is MED's current P/E ratio and EPS?
MED trades at a trailing P/E of -5.36 on trailing EPS of -1.8191895329820098 USD.
What do analysts rate MED?
Analyst consensus is "Hold" across 12 ratings (0 strong buy, 4 buy, 6 hold, 2 sell, 0 strong sell). Average 12-month price target: 12 USD.